Skip to main content
Erschienen in: World Journal of Surgery 10/2020

16.06.2020 | Original Scientific Report

Surgical Consideration Based on Lymph Nodes Spread Patterns in Patients with Peripheral Right Middle Non-small Cell Lung Cancer 3 cm or Less

verfasst von: Rulan Wang, Han-Yu Deng, Jie Zhou, Rui Jiang, Qinghua Zhou

Erschienen in: World Journal of Surgery | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

The optimal extent of lung resection and lymph nodes dissection for peripheral early-stage right middle non-small cell lung cancer (NSCLC) still remains controversial. In this study, we analyzed the patterns of lymph nodes metastasis (LNM) of patients with peripheral right middle NSCLC ≤ 3 cm, aiming to provide evidences for surgical choice for early-stage peripheral right middle lobe NSCLC.

Methods

We retrospectively investigated the clinical and pathological data of patients diagnosed with peripheral right middle lobe NSCLC ≤ 3 cm between January 2015 and December 2019. The LNM patterns were analyzed by tumor size.

Results

A total of 60 patients were included for analysis. The tumor size was preoperatively divided as follows: ≤ 1 cm (13 patients); > 1 cm but ≤ 2 cm (36 patients); > 2 cm but ≤ 3 cm (11 patients). Fifty-four patients were categorized as N0 group, 1 patient as N1 group, and 5 patients as N2 group. In the upper zone, 3 patients were found to have LNM. In the subcarinal zone, another 3 patients had LNM. But the lymph nodes of all these patients were negative in the lower zone. In station 10, 1 patient (1.67%) was found to have LNM, while in station 11–13, 2 patients (3.33%) were found to have LNM.

Conclusion

For the right middle lobe peripheral NSCLC ≤ 1 cm, sublobar resection with lymph node sampling may be a feasible treatment. For cancers > 1 cm but ≤ 2 cm, lobectomy with lobe-specific lymph node dissection (especially station 2R and 4R) may be a preferred choice. For tumors > 2 cm but ≤ 3 cm, lobectomy with systematic lymph node dissection may still be the standard of care.
Literatur
1.
Zurück zum Zitat Nasim F, Sabath BF, Eapen GA (2019) Lung cancer. Med Clin North Am 103:463–473CrossRef Nasim F, Sabath BF, Eapen GA (2019) Lung cancer. Med Clin North Am 103:463–473CrossRef
2.
Zurück zum Zitat Hirsch FR, Scagliotti GV, Mulshine JL et al (2017) Lung cancer: current therapies and new targeted treatments. The Lancet 389:299–311CrossRef Hirsch FR, Scagliotti GV, Mulshine JL et al (2017) Lung cancer: current therapies and new targeted treatments. The Lancet 389:299–311CrossRef
3.
Zurück zum Zitat Lu Y, Ma T, Wang L et al (2019) Advances in lymph node metastasis and lymph node dissection in early non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 22:520–525PubMed Lu Y, Ma T, Wang L et al (2019) Advances in lymph node metastasis and lymph node dissection in early non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 22:520–525PubMed
4.
Zurück zum Zitat Watanabe S (2014) Lymph node dissection for lung cancer: past, present, and future. Gen Thorac Cardiovasc Surg 62:407–414CrossRef Watanabe S (2014) Lymph node dissection for lung cancer: past, present, and future. Gen Thorac Cardiovasc Surg 62:407–414CrossRef
5.
Zurück zum Zitat Deng HY, Wang YC, Ni PZ et al (2017) Radiotherapy, lobectomy or sublobar resection? A meta-analysis of the choices for treating stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 51:203–210PubMed Deng HY, Wang YC, Ni PZ et al (2017) Radiotherapy, lobectomy or sublobar resection? A meta-analysis of the choices for treating stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 51:203–210PubMed
6.
Zurück zum Zitat Rusch VW, Asamura H, Watanabe H et al (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568–577CrossRef Rusch VW, Asamura H, Watanabe H et al (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568–577CrossRef
7.
Zurück zum Zitat Deng H-Y, Qin C-L, Li G et al (2018) Can lobe-specific lymph node dissection be an alternative to systematic lymph node dissection in treating early-stage non-small cell lung cancer: a comprehensive systematic review and meta-analysis? J Thorac Disease 10:2857–2865CrossRef Deng H-Y, Qin C-L, Li G et al (2018) Can lobe-specific lymph node dissection be an alternative to systematic lymph node dissection in treating early-stage non-small cell lung cancer: a comprehensive systematic review and meta-analysis? J Thorac Disease 10:2857–2865CrossRef
8.
Zurück zum Zitat Ishiguro F, Matsuo K, Fukui T et al (2010) Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score. J Thorac Cardiovasc Surg 139:1001–1006CrossRef Ishiguro F, Matsuo K, Fukui T et al (2010) Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score. J Thorac Cardiovasc Surg 139:1001–1006CrossRef
9.
Zurück zum Zitat Cerfolio RJ, Bryant AS (2006) Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. Ann Thorac Surg 81:1969–1973 (discussion 1973)CrossRef Cerfolio RJ, Bryant AS (2006) Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. Ann Thorac Surg 81:1969–1973 (discussion 1973)CrossRef
10.
Zurück zum Zitat Deng HY, Zhou J, Wang RL et al (2020) Lobe-specific lymph node dissection for clinical early-stage (cIA) peripheral non-small cell lung cancer patients: what and how? Ann Surg Oncol 27:472–480CrossRef Deng HY, Zhou J, Wang RL et al (2020) Lobe-specific lymph node dissection for clinical early-stage (cIA) peripheral non-small cell lung cancer patients: what and how? Ann Surg Oncol 27:472–480CrossRef
11.
Zurück zum Zitat Liang RB, Yang J, Zeng TS et al (2018) Incidence and distribution of lobe-specific mediastinal lymph node metastasis in non-small cell lung cancer: data from 4511 resected cases. Ann Surg Oncol 25:3300–3307CrossRef Liang RB, Yang J, Zeng TS et al (2018) Incidence and distribution of lobe-specific mediastinal lymph node metastasis in non-small cell lung cancer: data from 4511 resected cases. Ann Surg Oncol 25:3300–3307CrossRef
12.
Zurück zum Zitat Sakao Y, Okumura S, Mingyon M et al (2011) The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe. J Thorac Oncol 6:494–499CrossRef Sakao Y, Okumura S, Mingyon M et al (2011) The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe. J Thorac Oncol 6:494–499CrossRef
13.
Zurück zum Zitat Casal RF, Vial MR, Miller R et al (2017) What exactly is a centrally located lung tumor? Results of an online survey. Ann Am Thorac Soc 14:118–123CrossRef Casal RF, Vial MR, Miller R et al (2017) What exactly is a centrally located lung tumor? Results of an online survey. Ann Am Thorac Soc 14:118–123CrossRef
15.
Zurück zum Zitat Lardinois D, De Leyn P, Van Schil P et al (2006) ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 30:787–792CrossRef Lardinois D, De Leyn P, Van Schil P et al (2006) ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 30:787–792CrossRef
16.
Zurück zum Zitat Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51CrossRef Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51CrossRef
17.
Zurück zum Zitat Yang MZ, Hou X, Liang RB et al (2019) The incidence and distribution of mediastinal lymph node metastasis and its impact on survival in patients with non-small-cell lung cancers 3 cm or less: data from 2292 cases. Eur J Cardiothorac Surg 56:159–166CrossRef Yang MZ, Hou X, Liang RB et al (2019) The incidence and distribution of mediastinal lymph node metastasis and its impact on survival in patients with non-small-cell lung cancers 3 cm or less: data from 2292 cases. Eur J Cardiothorac Surg 56:159–166CrossRef
18.
Zurück zum Zitat Naruke T, Tsuchiya R, Kondo H et al (1999) Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg 16(Suppl 1):S17–24CrossRef Naruke T, Tsuchiya R, Kondo H et al (1999) Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg 16(Suppl 1):S17–24CrossRef
19.
Zurück zum Zitat Riquet M, Rivera C, Pricopi C et al (2015) Is the lymphatic drainage of lung cancer lobe-specific? A surgical appraisal. Eur J Cardiothorac Surg 47:543–549CrossRef Riquet M, Rivera C, Pricopi C et al (2015) Is the lymphatic drainage of lung cancer lobe-specific? A surgical appraisal. Eur J Cardiothorac Surg 47:543–549CrossRef
20.
Zurück zum Zitat Han H, Zhao Y, Chen H (2018) Selective versus systematic lymph node dissection (other than sampling) for clinical N2-negative non-small cell lung cancer: a meta-analysis of observational studies. J Thorac Disease 10:3428–3435CrossRef Han H, Zhao Y, Chen H (2018) Selective versus systematic lymph node dissection (other than sampling) for clinical N2-negative non-small cell lung cancer: a meta-analysis of observational studies. J Thorac Disease 10:3428–3435CrossRef
21.
Zurück zum Zitat Adachi H, Sakamaki K, Nishii T et al (2017) Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study. J Thorac Oncol 12:85–93CrossRef Adachi H, Sakamaki K, Nishii T et al (2017) Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study. J Thorac Oncol 12:85–93CrossRef
22.
Zurück zum Zitat Ma W, Zhang ZJ, Li Y et al (2013) Comparison of lobe-specific mediastinal lymphadenectomy versus systematic mediastinal lymphadenectomy for clinical stage T(1)a N(0) M(0) non-small cell lung cancer. J Cancer Res Ther 9(Suppl 2):S101–105PubMed Ma W, Zhang ZJ, Li Y et al (2013) Comparison of lobe-specific mediastinal lymphadenectomy versus systematic mediastinal lymphadenectomy for clinical stage T(1)a N(0) M(0) non-small cell lung cancer. J Cancer Res Ther 9(Suppl 2):S101–105PubMed
23.
Zurück zum Zitat Darling GE, Allen MS, Decker PA et al (2011) Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 141:662–670CrossRef Darling GE, Allen MS, Decker PA et al (2011) Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 141:662–670CrossRef
24.
Zurück zum Zitat Mitsos S, Panagiotopoulos N, Patrini D et al (2019) Is systematic lymph node dissection mandatory or is sampling adequate in patients with stage I non-small-cell lung cancer? Interact Cardiovasc Thorac Surg 28:550–554CrossRef Mitsos S, Panagiotopoulos N, Patrini D et al (2019) Is systematic lymph node dissection mandatory or is sampling adequate in patients with stage I non-small-cell lung cancer? Interact Cardiovasc Thorac Surg 28:550–554CrossRef
25.
Zurück zum Zitat Ding N, Mao Y, Gao S et al (2018) Predictors of lymph node metastasis and possible selective lymph node dissection in clinical stage IA non-small cell lung cancer. J Thorac Disease 10:4061–4068CrossRef Ding N, Mao Y, Gao S et al (2018) Predictors of lymph node metastasis and possible selective lymph node dissection in clinical stage IA non-small cell lung cancer. J Thorac Disease 10:4061–4068CrossRef
26.
Zurück zum Zitat Ye B, Cheng M, Li W et al (2014) Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 98:217–223CrossRef Ye B, Cheng M, Li W et al (2014) Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 98:217–223CrossRef
27.
Zurück zum Zitat Deng HY, Zhou J, Wang RL et al (2020) Surgical choice for clinical stage IA non-small cell lung cancer: view from regional lymph node metastasis. Ann Thorac Surg 109:1079–1085 Deng HY, Zhou J, Wang RL et al (2020) Surgical choice for clinical stage IA non-small cell lung cancer: view from regional lymph node metastasis. Ann Thorac Surg 109:1079–1085
28.
Zurück zum Zitat Lv X, Cao J, Dai X et al (2018) Survival rates after lobectomy versus sublobar resection for early-stage right middle lobe non-small cell lung cancer. Thorac Cancer 9:1026–1031CrossRef Lv X, Cao J, Dai X et al (2018) Survival rates after lobectomy versus sublobar resection for early-stage right middle lobe non-small cell lung cancer. Thorac Cancer 9:1026–1031CrossRef
29.
Zurück zum Zitat Kates M, Swanson S, Wisnivesky JP (2011) Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: a review of SEER data. Chest 139:491–496CrossRef Kates M, Swanson S, Wisnivesky JP (2011) Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: a review of SEER data. Chest 139:491–496CrossRef
30.
Zurück zum Zitat Yendamuri S, Sharma R, Demmy M et al (2013) Temporal trends in outcomes following sublobar and lobar resections for small (</= 2 cm) non-small cell lung cancers—a surveillance epidemiology end results database analysis. J Surg Res 183:27–32CrossRef Yendamuri S, Sharma R, Demmy M et al (2013) Temporal trends in outcomes following sublobar and lobar resections for small (</= 2 cm) non-small cell lung cancers—a surveillance epidemiology end results database analysis. J Surg Res 183:27–32CrossRef
31.
Zurück zum Zitat Dai C, Shen J, Ren Y et al (2016) Choice of surgical procedure for patients with non-small-cell lung cancer </= 1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol 34:3175–3182CrossRef Dai C, Shen J, Ren Y et al (2016) Choice of surgical procedure for patients with non-small-cell lung cancer </= 1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol 34:3175–3182CrossRef
32.
Zurück zum Zitat Lin G, Liu H, Li J (2019) Lobectomy versus sub-lobar resection in patients with stage IA right middle lobe non-small cell lung cancer: a propensity score matched analysis. J Thorac Dis 11:2523–2534CrossRef Lin G, Liu H, Li J (2019) Lobectomy versus sub-lobar resection in patients with stage IA right middle lobe non-small cell lung cancer: a propensity score matched analysis. J Thorac Dis 11:2523–2534CrossRef
33.
Zurück zum Zitat Razi SS, John MM, Sainathan S et al (2016) Sublobar resection is equivalent to lobectomy for T1a non-small cell lung cancer in the elderly: a surveillance, epidemiology, and end results database analysis. J Surg Res 200:683–689CrossRef Razi SS, John MM, Sainathan S et al (2016) Sublobar resection is equivalent to lobectomy for T1a non-small cell lung cancer in the elderly: a surveillance, epidemiology, and end results database analysis. J Surg Res 200:683–689CrossRef
34.
Zurück zum Zitat Dziedzic R, Zurek W, Marjanski T et al (2017) Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg 52:363–369CrossRef Dziedzic R, Zurek W, Marjanski T et al (2017) Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg 52:363–369CrossRef
35.
Zurück zum Zitat Jeon HW, Kim YD, Kim KS et al (2014) Sublobar resection versus lobectomy in solid-type, clinical stage IA, non-small cell lung cancer. World J Surg Oncol 12:215CrossRef Jeon HW, Kim YD, Kim KS et al (2014) Sublobar resection versus lobectomy in solid-type, clinical stage IA, non-small cell lung cancer. World J Surg Oncol 12:215CrossRef
37.
Zurück zum Zitat Pedersen JH, Saghir Z, Wille MM et al (2016) Ground-glass opacity lung nodules in the era of lung cancer ct screening: radiology, pathology, and clinical management. Oncology (Williston Park, NY) 30:266–274 Pedersen JH, Saghir Z, Wille MM et al (2016) Ground-glass opacity lung nodules in the era of lung cancer ct screening: radiology, pathology, and clinical management. Oncology (Williston Park, NY) 30:266–274
38.
Zurück zum Zitat Huang TW, Lin KH, Huang HK et al (2018) The role of the ground-glass opacity ratio in resected lung adenocarcinoma. Eur J Cardiothorac Surg 54:229–234CrossRef Huang TW, Lin KH, Huang HK et al (2018) The role of the ground-glass opacity ratio in resected lung adenocarcinoma. Eur J Cardiothorac Surg 54:229–234CrossRef
39.
Zurück zum Zitat Detterbeck FC, Homer RJ (2011) Approach to the ground-glass nodule. Clin Chest Med 32:799–810CrossRef Detterbeck FC, Homer RJ (2011) Approach to the ground-glass nodule. Clin Chest Med 32:799–810CrossRef
40.
Zurück zum Zitat Zha J, Xie D, Xie H et al (2016) Recognition of "aggressive" behavior in "indolent" ground glass opacity and mixed density lesions. J Thorac Dis 8:1460–1468CrossRef Zha J, Xie D, Xie H et al (2016) Recognition of "aggressive" behavior in "indolent" ground glass opacity and mixed density lesions. J Thorac Dis 8:1460–1468CrossRef
Metadaten
Titel
Surgical Consideration Based on Lymph Nodes Spread Patterns in Patients with Peripheral Right Middle Non-small Cell Lung Cancer 3 cm or Less
verfasst von
Rulan Wang
Han-Yu Deng
Jie Zhou
Rui Jiang
Qinghua Zhou
Publikationsdatum
16.06.2020
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 10/2020
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-020-05647-3

Weitere Artikel der Ausgabe 10/2020

World Journal of Surgery 10/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.